“Mal de Chagas” in Europa e in Italia: un problema sommerso Dr. Andrea Angheben Centro per le Malattie Tropicali Ospedale Sacro Cuore – Don Calabria Negrar www.tropicalmed.eu
“Mal de Chagas” in Europa e in Italia: un problema sommerso
Dr. Andrea AnghebenCentro per le Malattie Tropicali
Ospedale Sacro Cuore – Don CalabriaNegrar
www.tropicalmed.eu
Ten neglected tropical disease “hotspots” around the globe.
Hotez PJ (2014) Ten Global “Hotspots” for the Neglected Tropical Diseases. PLoS Negl Trop Dis 8(5): e2496.
doi:10.1371/journal.pntd.0002496
http://www.plosntd.org/article/info:doi/10.1371/journal.pntd.0002496
La malattia di Chagas è la principale malattia parassitaria per «burden» nelle Americhe
Cento e più anni di Malattia di ChagasKey facts
- About 6 million to 7 million people are estimated to be infected
worldwide, mostly in Latin America.
- Vector-borne transmission occurs in the Americas. The vector
is a triatomine bug that carries the parasite Trypanosoma cruzi which
causes the disease.
- Chagas disease was once entirely confined to the Region of the Americas – principally
Latin America – but it has now spread to other continents.
- The disease is curable if treatment is initiated soon after infection.
- In the chronic phase antiparasitic treatment can also prevent or curb/halt disease
progression.
- Up to 30% of chronically infected people develop cardiac alterations and up to 10%
develop digestive, neurological or mixed alterations which may require specific treatment.
- Vector control is the most useful method to prevent Chagas disease in Latin America.
- Blood screening is vital to prevent infection through transfusion and organ transplantation.
- Diagnosis of infection in pregnant women, their newborns and siblings is essential.
WHO fact sheet March 2015
Modalità di trasmissione
Rischio di trasmissione da:•contatto con Triatomina infetta: 0,1%•singola trasfusione di sangue (500 ml): 12-20%•trapianto renale da donatore in fase indeterminata: 35% • riattivazione in corso di immunodepressione: 30%• materno-fetale: 0,1-12%
Note epidemiologiche
Endemica in 21 Paesi dell’America Latina continentale
100 milioni di persone a rischio (25% della popolazione LA)
6-7 milioni di persone infettate (10000 decessi per anno) ↑↑↑ America Latina
Importanti variazioni endemicità tra Paesi
1.3%
1-5%
18-22%
1-5%
5-10%
1%
Aree GeografichePrevalenza
Migrazioni
La migrazione di individui affetti da malattia di Chagas pone un PROBLEMA DI SALUTE PUBBLICA NEI PAESI NON ENDEMICI…
Figure 1. Estimated number of Chagas disease cases in North America.
Hotez PJ, Dumonteil E, Betancourt Cravioto M, Bottazzi ME, Tapia-Conyer R, et al. (2013) An Unfolding Tragedy of Chagas Disease in North
America. PLoS Negl Trop Dis 7(10): e2300. doi:10.1371/journal.pntd.0002300
http://127.0.0.1:8081/plosntds/article?id=info:doi/10.1371/journal.pntd.0002300
Courtesy Ana Requena_Mendez – IsGlobal
An estimated 80.000-
120.000 cases*
90% yet unrecognized^*Jackson et al. Bull World Health Organ 2014;287:771–772
^Basile et al. Euro Surveill. 2011;16(37):19968
The estimated incidence for Europe in general is up to 35 cases per 100000
inhabitants, similar to the incidence of notified tuberculosis cases
Il tasso di sottodiagnosi è inaccettabile (99%)
Screening passivo (CMT) ed attivo (out-
reach activities) di soggetti a rischio
(soprattutto immigrati LA residenti in
Veneto-Lombardia):
1998-03/2013: 2799 persone screenate presso CMT
Risultati: Discordanti 72 = 2,57%
Positivi: 455 = 16,26%
Negativi: 2224 = 79,45
2% circa da classificare/eseguire
NB: “bias di selezione” del campione
CD control: pitfalls and obstacles
Disease features: long silent phase, aspecific symptoms,
low awareness (healthcare professionals, communities)
Migration factors: patchy distribution, internal migration,
economic problems and administrativeconstrains, fear of stigma
Unpreparedness: missing knowledge, low attention by
public health, no political committment, scarse coordination
CARATTERISTICHE CLINICHE DELLA MALATTIA
Modified from Rassi, The Lancet 2010
Storia naturale della malattia di Chagas
Neurologic
20-30% 10% <5%70% 10%
La clinica quindi
• È spesso assente (sia fase acuta >95%, che cronica 70%)
• Quando presente, è spesso aspecifica (febbricola in fase acuta, BBdx, bradicardia, stipsi nella cronica…)
• Diagnosi non facile/alla portata di tutti i laboratori
• Lunghissimo periodo tra acquisizione e manifestazione clinica/diagnosi
• Unawareness del paziente e del medico
CONTROLLO DELLA TRASMISSIONE:
(UN)PREPAREDNESS
Trasfusioni di sangue e Chagas
• La donazione di sangue spiega il 10% dei casi di Chagas.
• 20% di rischio di trasmissione
• Prevenzione? Screening universale (Francia) vs selettivo (USA, Spagna, UK…) o esclusione donatore a rischio
• Metodi inattivazione non efficaci
Selective
screening
2005
2013
1999
2009
Selective
screening
Selective
screening
(2004/33/CE and 2006/17/CE)
• A guideline from the Council of Europe entitled “Guide to preparation Use and Quality Assurance of Blood Components” (16th edition) specifically recommends performing a validated test for T. cruzi infection in donors at risk (born or have been transfused in endemic areas)
• Accordingly, the EU directive is currently out of step with the Council of Europe’s recommendations.
Policiy re-evaluation after at
least 6 months of blood donor
screening
Policiy re-evaluation after
ElCid project data collection
(2010/45/EU
B*GB^
S*§
wo
rk in
pro
gre
ss o
n a
nte
na
tal scre
en
ing
in
se
lce
ted
ce
ntr
es –
ElC
id P
roje
ct
^ w
ork
in
pro
gre
ss o
n a
nte
na
tal scre
en
ing
via
the
Ad
vis
ory
Co
mm
itte
e fo
r D
an
ge
rou
s
Path
ogens
* ra
isin
g a
wa
ren
ess a
mo
ng
st g
yn
eco
log
ists
D§
In merito al rapporto di costo/efficacia dello screening per malattia di Chagas in gravidanza è recentemente stato pubblicato uno studio spagnolo (Sicuri et al., 2011) che ne ha solidamente dimostrato i vantaggi.
Screening materno-infantile: fattibile?
Results
“Italia” 1,4%(Angheben et al., 2011)
Malattia di Chagas: focolai di trasmissione orale alimenti
2 viaggiatori italiani:
1) 2005 Santa Catarina (Brasile) da ingestione di succo di canna da zucchero (trattato e guarito, MO)
2) Turista “avventuroso” recatosi in Amazzonia (scoperto a Roma perchè donatore di sangue, Gabrielli S et al. Blood Transfus. 2013 Oct;11(4):558-62. doi: 10.2450/2013.0055-13)
Trasmissione orale
FATTORI LEGATI ALLA MIGRAZIONE/STATO DI
MIGRANTE
La migrazione italiana in America Latina
Tre ondate migratorie:
‘800: 106 emigranti partono da Genova a Santos (Brasile) fino al 1920 15-18X106 di emigrati
II ondata dopo le guerre mondiali
II ondata: professionisti e imprenditori
La migrazione latinoamericana in Italia Migrazione di ritorno (crisi economica)
Iniziata negli anni ’70
Accresciutasi soprattutto dall’anno 2000 e poi 2003 (legge Bossi-Fini del 2002corca 70000 regolarizzazioni)
Femminilizzazione elevata delle presenze (60-70%)
Un quinto dei matrimoni misti è fra donna LA e italiano
Ecuadorians: Genova 16800; Milan 13500 out
of 91000 residents in 2010
Bolivians: Bergamo 4000; Milan 1200 out of
13000 residents in 2010
Brazilians: Rome 3400; Milan 3200; Turin 2000
out of 46700 residents in 2010;
Lumbardy 13500; Veneto 6200; Lazio 5300
www.comuni-italiani.it
Ad
ult
tri
cycl
e “P
ash
ley
Tri-
1”
(htt
p:/
/ww
w.p
ash
ley.
co.u
k/p
rod
uct
s/p
icad
or.
htm
l)
Patient care: diagnosis & treatment
of congenital, acute and chronic
cases
Stop transmission: blood transfusion, organ
transplantation,vertical transmission
Chagas disease burden
Information & surveillance: Cases, transmission routes,
healtcare…
Courtesy of Pedro Albajar-Viñas, WHO’s control strategy
The “tricycle strategy”
The NECI aims
to: • Control Chagas disease in NECs• Contribute to global efforts to eliminate Chagas disease
The Non-Endemic Countries Initiative (NECI)
In 2007, WHO and PAHO convened a meeting with Chagas disease endemic and non-endemic countries.
The presence of T. cruzi infection outside Latin America has been recognized from the 28 participating countries
Courtesy of Guido Benedetti, Global Health Center – Tuscany Region - modified
David Gray/Reuters 2012 (http://www.ifrasia.com/waiting-for-a-lift/21027619.article)
Courtesy of Pedro Albajar-Viñas, WHO
John Meckley 2007 (http://www.flickr.com/photos/meckleychina/2050239366/in/pool-1498067@N21/)
Courtesy of Pedro Albajar-Viñas, WHO
FIRST SPANISH CONSENSUS DOCUMENTon Imported Chagas Disease (2005)
People WHO:
Have been born in endemic countries.
Have been born from mothers from endemic countries.
Have traveled > 1 month to rural endemic areas.
Have received a blood transfusion in endemic countries.
Screening and Diagnosis
WHO SHOULD BE SCREENED / OFFERED SCREENING ?
And WHO:
Want to donate blood and or organs / tissues.
Are pregnant women.
Have clinical symptoms compatible with Chagas Disease.
Are going to undergo immunodepression.
Screening of asymptomatic persons was not considered (2005)
+
Ch
ag
as
dis
ea
se:
imm
igra
nt
healt
h
pro
jec
ts/p
rog
ram
s
ElCid
05/2014
= Institutional/Local initiatives
Chagas Disease in Europe: asymptomatic people screening?
Treating women before pregnancy prevents congenital transmission
Cost-effective to screen LA mothers, newborns and relatives of positive women. If high
prevalence from mother to all relatives
Cost-
effectiveness
screening
study
ongoing –
IsGlobal,
Barcelona
Thanks